Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP ...

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...

The Foster City, Calif.-based biopharmaceutical company said the growth was driven by Biktarvy, Descovy, Trodelvy and ...

This update makes Biktarvy the only second-generation integrase strand transfer inhibitor-based single-tablet regimen with in-label clinical trial data and FDA approval in virologically suppressed ...

Gilead Sciences’ Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets) has been approved by the ...

Biktarvy is a complete HIV treatment that combines three powerful medicines to form the smallest 3-drug, integrase strand transfer inhibitor (INSTI)-based single-tablet regimen (STR) available ...

Results showed that after switching to Biktarvy, 100% of patients 6 to <12 years of age and 98% of patients 12 to <18 years of age remained virologically suppressed (HIV-1 RNA <50 copies/mL).

Biktarvy is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral (ARV) treatment history or to ...

Gilead Sciences Inc.'s drug Biktarvy has been approved for the treatment of HIV-1 in China, the company said Friday. The China National Medical Products Administration approved the drug as a ...

Biktarvy is currently approved as a complete regimen for the treatment of HIV-1 infection in adults with no antiretroviral treatment history or to replace the current antiretroviral regimen in ...